Sarepta Therapeutics (SRPT) – FDA
-
Sarepta stock jumps on FDA nod for ELEVIDYS gene therapy
-
Sarepta Therapeutics (SRPT) Climbs 20% After Announcing U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to SRPT Stock Lookup